Sign In
Buy CODX
$5.17
-1.05 (-16.88%)
At Close: Jun 03, 2026
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q4 2021 Results - Earnings Call Transcript
07:49pm, Thursday, 24'th Mar 2022
Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q4 2021 Results - Earnings Call Transcript
Co-Diagnostics clocks up $97.9M in full year 2021 revenue on the strength of Logix Smart COVID-19 test sales
04:53pm, Thursday, 24'th Mar 2022
Co-Diagnostics (NASDAQ:CODX) Inc saw a healthy jump in year-over-year revenue driven by global sales of its Logix Smart COVID-19 tests, according to its latest financial results. The molecular diagnos
Why Co-Diagnostics Stock Is Trading Higher After Hours
04:35pm, Thursday, 24'th Mar 2022
Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher in Thursday's after-hours session after the company reported financial results and issued earnings guidance. Co-Diagnostics reported full ye
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Novartis Announces FDA Approval Of Prostate Cancer Drug Pluvicto
Novartis AG (NYSE: NVS) said the U.S.
HealthEquity (HQY) Q4 Earnings Miss Estimates
09:25pm, Tuesday, 22'nd Mar 2022 Zacks Investment Research
HealthEquity (HQY) delivered earnings and revenue surprises of -4.76% and 2.02%, respectively, for the quarter ended January 2022. Do the numbers hold clues to what lies ahead for the stock?
Co-Diagnostics, Inc. to Present at MarketsandMarkets Conference on March 23-24 in London, England
09:30am, Tuesday, 22'nd Mar 2022
SALT LAKE CITY , March 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular d
Co-Diagnostics adds four new experts to its Scientific Advisory Board
11:06am, Thursday, 17'th Mar 2022
Co-Diagnostics (NASDAQ:CODX) Inc has beefed up its Scientific Advisory Board with the addition of four new experts. The molecular diagnostics company is welcoming Idaho Technology/BioFire CSO Carl Wit
CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?
06:30am, Wednesday, 16'th Mar 2022 Zacks Investment Research
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?
03:46am, Wednesday, 16'th Mar 2022
CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price
Why Co-Diagnostics Is Soaring Today
05:15pm, Tuesday, 15'th Mar 2022 The Motley Fool
The diagnostics and research outfit gave investors a dose of good news today.
Co-Diagnostics announces $30M buyback program (NASDAQ:CODX)
01:36pm, Tuesday, 15'th Mar 2022 Seeking Alpha
Co-Diagnostics <> has received Board''s approval to repurchase up to $30M of its common share under the new buyback program. "This share repurchase program is aligned with…
Why Co-Diagnostics Is Soaring Today
01:15pm, Tuesday, 15'th Mar 2022
The diagnostics and research outfit gave investors a dose of good news today.
Why Co-Diagnostics Shares Are Trading Higher Today
11:16am, Tuesday, 15'th Mar 2022
Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher Tuesday after the company announced its board authorized a share repurchase program, allowing Co-Diagnostics to repurchase up to $30 mil
Biodesix, Inc. (BDSX) Reports Q4 Loss, Lags Revenue Estimates
11:15am, Monday, 14'th Mar 2022 Zacks Investment Research
Biodesix, Inc. (BDSX) delivered earnings and revenue surprises of 2% and 1.45%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 EARNINGS RELEASE DATE AND WEBCAST
09:30am, Monday, 14'th Mar 2022
SALT LAKE CITY , March 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests
